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Abstract 
Background: Uncoordinated cellular proliferation and dysregulated angiogenesis in solid tumors are coupled with 
inadequate tissue, blood, and lymphatic vascularization. Consequently, tumors are often characterized by hypoxic 
regions with limited access to vascular‑borne substances. In particular, systemically administered nanoparticles (NPs) 
targeting tumor cells and relying on vascular access to reach tumor tissue can suffer from limited therapeutic efficacy 
due to inhomogeneous intra‑tumor distribution and insufficient cellular internalization of NPs. To circumvent these 
challenges, NP surfaces can be modified to facilitate tumor interstitial transport and cellular uptake.
Results: We create poly(lactic‑co‑glycolic) acid NPs modified with MPG, polyethylene glycol (PEG), MPG/PEG, and 
Vimentin (VIM), and evaluate their cellular uptake in 2D (monolayer) cell culture of human cervical carcinoma (HeLa). 
We compare NP performance by evaluating uptake by non‑cancerous vaginal (VK2) cells. We further assess NP inter‑
stitial transport in hypo‑vascularized lesions by evaluating the effect of the various modifications on NP penetration in 
3D cell culture of the HeLa cells. Results show that after 24 h incubation with HeLa cells in monolayer, MPG, MPG/PEG, 
PEG, and VIM NPs were internalized at 66×, 24×, 30×, and 15× that of unmodified NPs, respectively. In contrast, incu‑
bation with VK2 cells in monolayer showed that MPG , MPG/PEG , PEG , and VIM NPs internalized at 6.3×, 4.3×, 12.4×, 
and 3.0× that of unmodified NPs, respectively. Uptake was significantly enhanced in tumorigenic vs. normal cells, 
with internalization of MPG NPs by HeLa cells being twice that of PEG NPs by VK2 cells. After 24 h incubation in HeLa 
3D cell culture, MPG and MPG/PEGNPs were internalized 2× and 3× compared to PEG and VIM NPs, respectively. 
Whereas MPG NPs were internalized mostly in the cell culture periphery (1.2×, 1.4×, and 2.7× that of PEG, MPG/PEG, 
and VIM NPs, respectively), PEG NPs at 250 μm penetrated 2× farther into the tissue culture than MPG NPs. For all NP 
types, cellular internalization was severely hindered in 3D compared to monolayer.
Conclusions: Although MPG surface modification enhances internalization and uptake in hypo‑vascularized cervical 
tissue culture, coating with PEG reduces this internalization while enhancing penetration. A delivery strategy com‑
bining NPs with either modification may balance cellular internalization vs. tissue penetration in hypo‑vascularized 
cervical cancer lesions.
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Background
Cervical cancer is the third most common gynecologic 
cause of cancer associated with patient fatalities. Approx-
imately 13,000 new cases of invasive cervical cancer are 
diagnosed yearly, of which 30  % prove fatal. In the US, 
cervical cancer primarily afflicts women younger than 50; 
however, in countries without established screening and 
prevention programs, cervical cancer remains the second 
most common type of cancer and cause of death among 
all female cancers [1–3]. Screening tests and vaccines 
have contributed to a decrease in cases; to date, there are 
3 approved vaccines against cervical cancer. These vac-
cines, Gardasil®, Gardasil® 9, and Cervarix®, aim at pre-
venting cancers originating from HPV types 16 and 18, 
which are attributed to ~70 % of cervical cancers [4]. Yet 
despite this efficacy, the vaccines only protect against a 
subset of all known HPV strains [4–6]. The inadequacy of 
vaccination, coupled with the fact that vaccination is not 
widespread [5, 6], maintains the risk of cervical cancer as 
a fatal disease.
Relative to the success of prophylactic vaccines, inef-
fective treatment options exist for established HPV infec-
tions and cervical cancer originating from HPV. This is 
primarily attributed to multidrug resistance and chemo-
therapeutic side effects. Despite early stage tumor iden-
tification and established eradication methods including 
surgery and radiation, the adverse side effects of these 
treatment strategies often result in negative gynecologic 
and obstetric outcomes. In comparison to surgical and 
radiation challenges, even systemic chemotherapy results 
in relatively low transport efficiency, resulting in high 
chemotherapeutic doses needed to target mucosal and 
epithelial tissue [7–10]. Due to the high systemic toxicity 
induced by systemic chemotherapy, new treatment strat-
egies are urgently needed.
In addition to these clinical challenges, successful 
therapeutic agent delivery to the tumor microenviron-
ment requires minimizing agent degradation and excre-
tion, avoidance of immunogenic interactions, adequate 
penetration and distribution throughout the tumor tis-
sue, cellular uptake and internalization, and sufficient 
cytotoxicity [11]. United States Food and Drug Admin-
istration (FDA)-approved materials may be selected 
as nano-scale drug carriers that have been proven to 
be non-inflammatory and non-toxic while enabling 
the delivery of highly localized concentrations of both 
hydrophilic and hydrophobic agents [11–13]. In particu-
lar, polymer nanoparticle-based drug delivery systems 
have been evaluated as attractive options for efficacious 
delivery of agents such as drugs and genes with result-
ing treatment efficacy [12, 13]. The pharmacokinetics of 
polymeric systems can be tailored by changing the poly-
mer monomer concentrations to facilitate agent diffusive 
transport, typically via a combination of burst and sus-
tained release profiles.
Besides enabling the sustained release of encapsulated 
agents, relative to systemic options, local intravaginal 
therapy may represent a relatively non-invasive approach 
to locally treat cervical tumors [7]. Nanoparticles (NP) can 
be modified to minimize unwanted systemic interactions, 
prolong bioavailability, promote targeted delivery to the 
physiologic site of interest, and enhance tumor penetra-
tion and cellular uptake [14]. Different types of NP surface 
modifications can be utilized to elicit these desired behav-
iors. Stealth coatings such as polyethylene glycol (PEG) 
can decrease unwanted systemic interactions and neu-
tralize the carrier’s surface charge [15, 16], while targeting 
ligands can increase the specificity of conjugated carriers 
to systemically target the desired physiological environ-
ment [17]. Cell penetrating peptides, such as MPG, RGD, 
and TAT, are examples of short ligands that can enhance 
the cellular internalization of their conjugated carriers 
[18–29]. In particular, previous studies have shown that 
NP surface modification with the amphipathic, synthetic 
peptide MPG derived from HIV gp41 and SV40 [24, 30] 
displays high cellular binding and internalization achieved 
via clathrin-mediated endocytotic uptake [31].
Tumor tissue is typically characterized by an overabun-
dance of extracellular matrix as well as poorly vascular-
ized areas, both of which can hinder diffusive transport of 
NPs [11]. Thus, in addition to evaluating cellular uptake 
capability, delivery systems would benefit from testing in a 
three-dimensional (3D) environment which more closely 
represents hypo-vascularized tumor lesions. For this pur-
pose, 3D cell culture provides a suitable platform [32, 33] 
that is more controllable than tumors in vivo. Previously, 
3D cell culture has been employed to study the behavior 
of various nano-carriers, such as gold and polymeric NPs. 
It has been shown both experimentally [34–38] and theo-
retically [39–49] that NPs require appropriate character-
istics and surface modifications to adequately penetrate 
hypo-vascularized regions for effective therapeutic deliv-
ery, even if cellular internalization is optimized.
With the goal to enhance both the transport and 
internalization of therapeutic agents in hypo-vascular-
ized tumor tissue, in this study we evaluate a variety of 
poly(lactic-co-glycolic) acid (PLGA) NP formulations 
for tissue penetration and cellular internalization. The 
NPs were modified with either a cell penetrating peptide 
(MPG), a stealth ligand (PEG), a tumor targeting cell pen-
etrating peptide (Vimentin tubulin binding site peptide, 
VIM) [50, 51], or a hybrid modification with both cell 
penetrating peptides and stealth ligands (MPG/PEG). 
These ligands were chosen because they have already 
been individually well characterized to enhance cell inter-
nalization, e.g., as we have previously shown for MPG 
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[31]. We assess how the NP surface modifications affect 
uptake in cervical tumor cells, and compare the NP per-
formance in normal vaginal cells. We further evaluate the 
NP transport and internalization in a 3D spheroid model 
representing hypo-vascularized cervical cancer lesions.
Results
Nanoparticle characterization
The NP surface was first modified with avidin-palmitate, 
and different NP groups were created based on the addition 
of one of the following biotinylated ligands: MPG, MPG/
PEG, PEG, or VIM, as described in  the “Methods” sec-
tion. Figure 1 illustrates the NPs used in this study, while 
Additional file  1: Figure S1 shows a representative scan-
ning electron microscopy (SEM) image of the unmodified 
NPs and their size distribution. The average unhydrated NP 
diameter measured 167 ± 50 nm. Hydrodynamic sizes and 
surface charges for the different NP groups were quantified 
via dynamic light scattering (DLS) and zeta potential meas-
urements, respectively (Additional file 1: Table S1).
Unmodified NPs had a hydrodynamic diameter 
of 267  ±  13.6  nm and a negative surface charge of 
−17.3  ±  0.5  mV, and the addition of avidin-palmitate 
increased this surface charge to −14.3  ±  0.59  mV. The 
surface charge was further increased with the addition 
of the ligands, with MPG-modified NPs having the most 
positive charge at −0.4 ±  0.2 mV, followed by PEG and 
MPG/PEG with −5.2 ± 1.3 and −5.3 ± 0.7 mV, respec-
tively, and VIM with −11.1 ± 1.0 mV. NP hydrodynamic 
sizes ranged from 232 to 277  nm for both unmodified 
and surface-modified groups, with no statistically signifi-
cant difference between the groups.
Uptake of PLGA‑modified nanoparticles in cervical cancer 
cell monolayers
Cellular association (binding plus internalization) and 
internalization in 2D cell culture monolayers were 
quantitatively assessed using Fluorescence Activated 
Cell Sorting (FACS) with cervical tumor epithelial cells 
(HeLa) and normal vaginal epithelial cells (VK2) (Fig. 2). 
Both HeLa and VK2 cells were incubated with the same 
concentration of NPs (0.05  mg/mL) for 1.5 or 24  h, 
regardless of modification. For HeLa cells, all of the mod-
ified NP groups showed both greater total association as 
well as internalization relative to unmodified NPs at both 
time points. At 1.5  h, MPG, MPG/PEG, PEG, and VIM 
NPs were internalized at 607×, 184×, 79×, and 57× that 
of unmodified NPs, respectively (Fig. 2a). Comparing the 
formulations to each other, the MPG NPs showed 3.3×, 
7.6×, and 10.5× greater internalization than the MPG/
PEG, PEG, and VIM NPs, respectively. After 24 h of incu-
bation, MPG, MPG/PEG, PEG, and VIM NPs were inter-
nalized at 66×, 24×, 30×, and 15× that of unmodified 
NPs, respectively (Fig. 2b). The MPG NPs were internal-
ized at 2.7×, 2.2×, and 4.5× that of MPG/PEG, PEG, and 
VIM NPs, respectively. Since the internalization for the 
MPG NPs was essentially the same at both time points, 
these data highlight the increase in internalization of the 
other formulations after longer exposure times.
Uptake of PLGA‑modified nanoparticles in vaginal 
epithelial cell monolayers
In contrast, NP association with VK2 cells at 1.5  h was 
not as distinct between the various modified formula-
tions (Fig.  2c), whereas PEG NPs internalized at 2.1×, 
5.9×, and 8.8× compared to MPG, MPG/PEG and 
VIM NPs, respectively. Comparing to unmodified NPs, 
the MPG, MPG/PEG, PEG, and VIM NPs internalized 
respectively at 20×, 7×, 43×, and 5×. After 24  h how-
ever, a clearer separation in association was apparent and 
PEG NPs were internalized at 1.9×, 2.8×, and 4.0× com-
pared to MPG, MPG/PEG, and VIM NPs, respectively 
(Fig. 2d).
The internalization remained invariant when com-
paring MPG and PEG between the two time points, 
while the internalization of MPG/PEG and VIM essen-
tially doubled. When compared to unmodified NPs 
after 24  h incubation, the MPG, MPG/PEG, PEG, and 
Fig. 1 Schematic illustrating NP formulations used in this study
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VIM internalized at 6.3×, 4.3×, 12.4×, and 3.0× that of 
unmodified NPs.
Comparison of nanoparticle uptake between tumorigenic 
and normal cell monolayers
Of note after 24 h, the unmodified NPs readily associate 
with the VK2 cells, in contrast to HeLa cells; however, 
unmodified NPs demonstrate low levels of internaliza-
tion in both cell lines. In contrast, surface-modified NP 
uptake was significantly enhanced in both the HeLa and 
VK2 cell lines. MPG NPs were internalized the most in 
HeLa cells; whereas PEG NPs were internalized most 
highly in VK2 cells. While both surface-modified groups 
(MPG and PEG) demonstrated strong internalization 
in HeLa and VK2 cells respectively, MPG was internal-
ized in HeLa cells 2× that of the PEG NPs by the VK2 
cells. When comparing between the earlier and later 
time points, it is apparent that the PEG NPs showed the 
highest increase in both association and internalization 
by the longer exposure with the tumorigenic HeLa but 
not with the normal VK2 cells. Cellular association and 
internalization were qualitatively assessed via inverted 
epifluorescence microscopy for both HeLa and VK2 cells 
at 1.5 h (Additional file 1: Figures S2, S3) and 24 h incuba-
tion times (Figs. 3, 4). Although the images for the most 
part reflect the flow cytometry results in Fig. 2, they are 
representative samples providing a limited assessment.
Uptake of PLGA‑modified nanoparticles 
in hypo‑vascularized cancer lesions
Cellular association and internalization in 3D cell cul-
ture (HeLa cervical tumor spheroids), incubated with the 
same concentration of NPs (0.05 mg/mL) as the monolay-
ers, were quantitatively assessed at 1.5 and 24 h via flow 
cytometry (Fig. 5). At 1.5 h, as a group, all of the modi-
fied NPs had higher association than the unmodified 
NPs, with statistically similar association when compared 
to each other. The surface-modified NPs also evinced a 
statistically similar internalization when compared to 
each other, but in this case, as a group the MPG, MPG/
PEG, and VIM NPs showed higher internalization than 
the unmodified and PEG NPs (Fig. 5a). In contrast, after 
Fig. 2 Cellular association and internalization of the various NP formulations are presented for HeLa (top) and VK2 (bottom) cells, shown at 1.5 h 
(left) and 24 h (right). Statistically similar results are shown linked with an overbar
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Fig. 3 Total NP association (binding and internalization) in monolayers of HeLa cells after 24 h incubation. Nuclei are blue (Hoechst), actin cytoskel‑
etons are red (Texas red phalloidin), and NPs are green (Coumarin 6). Bar 50 μm
Fig. 4 Total NP association (binding and internalization) in monolayers of VK2 cells after 24 h incubation. Nuclei are blue (Hoechst), actin cytoskel‑
etons are red (Texas red phalloidin), and NPs are green (Coumarin 6). Bar 50 μm
Page 6 of 12Sims et al. J Nanobiotechnol  (2016) 14:33 
24  h, the unmodified and surface-modified NPs (except 
for VIM, which was lower) showed statistically similar 
association (Fig. 5b), while MPG and MPG/PEG showed 
2× and 3× internalization relative to PEG and VIM NPs, 
respectively. Interestingly, unlike the results obtained 
with the monolayer, in the 3D cell culture the associa-
tion of all NPs increased significantly at 24 h compared to 
the 1.5 h time point: unmodified by 4.8×, MPG by 2.6×, 
MPG/PEG by 3.0×, PEG by 1.6×, and VIM by 1.6×. 
Internalization also increased at the later time point, with 
MPG and MPG/PEG NPs being internalized the most 
(at 3.6× and 3.8× compared to 1.5 h, respectively), while 
VIM or unmodified versions were internalized the least.
Comparison of nanoparticle uptake between 2D and 3D 
cell cultures
In general, all of the values measured from 3D cell cul-
tures were lower than those from the 2D cell cultures, 
highlighting the effect of the diffusive transport barrier 
in hypo-vascularized tissue. Figure 6 summarizes the NP 
cellular internalization as a function of surface modifi-
cation, cell culture type, and treatment duration, high-
lighting the effect of diffusive transport on NP uptake 
between the monolayer and tumor environments. It 
is expected that monolayer culture represents optimal 
conditions in terms of diffusive transport, and therefore 
association and internalization would be lower in the 3D 
tumor environment.
Transport of PLGA‑modified nanoparticles 
in hypo‑vascularized cancer lesions
The NP diffusion profiles after 1.5  h through the sphe-
roid tissue are presented in Fig. 7, showing that MPG and 
PEG-modified NPs exhibited the greatest fluorescence 
intensity averaged over 200 × 80 μm areas, followed by 
MPG/PEG and VIM NPs. In particular, MPG NPs were 
heavily detected in the periphery (within 100 μm of the 
edge) of the spheroids, viz., 2×, 1.4×, and 2.7× that of 
Fig. 5 Cellular association and internalization of the various NP formulations in HeLa cell tumor spheroids. Results are shown at (a) 1.5 and (b) 24 h. 
Statistically similar results are shown linked with an overbar
Fig. 6 Comparison of NP cellular internalization between HeLa monolayer and spheroid cell cultures. Results are shown at (a) 1.5 and (b) 24 h
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PEG, MPG/PEG, and VIM NPs, respectively, while PEG 
NPs penetrated 2× farther (250  μm) into the spheroid 
than the MPG NPs. In comparison, unmodified NPs 
exhibited the lowest detection and penetration into the 
tumor spheroids. Representative images for each NP type 
are shown in Additional file 1: Figure S4.
Discussion
Building upon our previous work using avidin-palmitate 
PLGA NPs with modified surface chemistry [31], here we 
study the effects of contrasting and hybrid surface modi-
fications on NP transport and cellular internalization in 
cervical tumor cells. Previously, avidin-palmitate NPs 
conjugated with the cell-penetrating peptide MPG were 
shown to have rapid internalization in monolayer cervi-
cal carcinoma (HeLa) cells, with a significant improve-
ment over unmodified NPs. Here, we expand the suite 
of NP surface modifications to include PEG, VIM, and 
a hybrid modification of MPG and PEG. These formula-
tions were evaluated for their internalization over short 
and extended time periods (1.5 and 24 h, respectively) in 
monolayer cell culture, representing optimal transport 
conditions, and in tumor spheroid cultures, representing 
hypo-vascularized tumor lesions with diffusive transport 
limitations. Additionally, we extend our analysis beyond 
cancerous cells to include normal vaginal cells (VK2) to 
assess potential differences in the efficacy of different 
surface modifications when targeting tumor versus non-
tumor cells present in the female reproductive tract.
The NP formulations were characterized using stand-
ard methods to evaluate size, hydrodynamic size, and 
zeta potential (Additional file  1: Figure  S1; Table  S1). 
Unmodified NPs exhibited the most negative surface 
charge, while surface modification increased the surface 
potential to more positive values. MPG NPs exhibited 
the greatest increase in surface potential, as MPG is an 
amphipathic peptide that contains a cationic sequence 
known to enhance cell surface interaction. All NP surface 
modifications yielded an improvement in cellular asso-
ciation and internalization over unmodified NPs under 
optimal transport conditions in HeLa monolayer cell 
culture (Fig. 2a, b). MPG-modified NPs had the highest 
cellular association and internalization at both 1.5 and 
24  h, indicating their potential to efficaciously promote 
NP uptake. The hybrid MPG/PEG NPs showed signifi-
cantly enhanced uptake at 1.5 h, greater than both PEG 
and VIM-modified NPs. However, PEG significantly 
increased cellular internalization after a longer expo-
sure time and surpassed the hybrid MPG/PEG NPs. The 
MPG, VIM, and hybrid NPs showed modest improve-
ment in internalization after longer treatment duration. 
These results are in agreement with our previous work 
that MPG-modified NPs have a rapid mechanism of 
uptake in HeLa cells [31] while PEG-modified NPs take 
longer to internalize. This is consistent with PEG func-
tionality, which is designed to prolong half-life in vivo.
In contrast, in normal vaginal cells (VK2), PEG-mod-
ified NPs exhibited similar high uptake and internaliza-
tion at 1.5 and 24  h (Fig.  2c, d), while MPG and MPG/
PEG NPs showed only slight internalization. In fact, the 
MPG-modified NPs demonstrated greater than threefold 
improvement in internalization by cancerous relative to 
normal cells. These results suggest that the association 
and uptake of these NPs in normal cells may be mediated 
by different molecular mechanisms or cell surface moie-
ties than in cancerous cells, which may have significant 
implications in more specific targeting of cancer lesions. 
The results further suggest that while VIM NPs are more 
efficacious than unmodified NPs, VIM most likely does 
not serve a specific targeting purpose for these cells. 
Enhancement is most likely due to the slightly more posi-
tive surface potential compared to that of the unmodi-
fied NPs. The high internalization of PEG-coated NPs in 
the VK2 cells, and also after 24 h in HeLa cells, indicates 
that these NPs might provide a means to enhance trans-
port and concentration of therapeutics into normal vagi-
nal tissue, while also offering the potential for enhanced 
uptake in cancerous cells.
Following the assessment of cellular internalization 
in optimally diffusive (monolayer) conditions, a similar 
evaluation was performed in 3D cell culture of HeLa cells 
to assess the transport and uptake of these NPs in hypo-
vascularized tumor tissue. After the short incubation 
of 1.5  h, all surface-modified NPs performed similarly 
(Fig.  5), demonstrating slightly increased internaliza-
tion relative to the unmodified NPs. After 24 h, the MPG 
and MPG/PEG NPs exhibited the most internalization 
relative to the other NP groups. Unlike the monolayer 
cultures, none of the groups saturated the spheroids at 
Fig. 7 NP penetration into 3D cell culture (HeLa spheroids) after 1.5 h 
incubation
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1.5 h, and instead elicited a more gradual, yet significant 
increase in internalization with longer exposure time. 
These results highlight the diffusive transport limita-
tion through the 3D tissue culture as a time-dependent 
process, and enable a more detailed assessment of NP 
performance. The transport limitation in 3D tissue is 
well known (e.g., [52–56]), and derives from the extra-
cellular matrix as well as cell–matrix and cell–cell inter-
actions (such as E-cadherin) impeding diffusive flow [57, 
58]. Whereas in monolayer HeLa and VK2 cell cultures 
the MPG and PEG NPs were internalized the most com-
pared to the other groups, in the 3D cell culture the MPG 
and MPG/PEG NPs showed highest internalization. The 
diffusive transport limitation is further emphasized in 
Fig. 6, which compares the 2D and 3D internalization of 
the NPs in monolayer versus spheroid cultures.
As shown in Fig.  7, PEG NPs have the greatest depth 
of penetration into the spheroid tissue, with maximal 
concentration reached at 125 μm. In contrast, the MPG 
NPs achieved the highest concentration along the tumor 
periphery (maximally at 65  μm), but were unable to 
fully penetrate it. As shown in the monolayer, MPG NPs 
have the highest rate of cellular internalization, which 
is critical to the success of some biological therapeutics 
that cannot transverse cellular membranes alone, such 
as oligonucleotides, but this increased internalization 
may limit the depth of penetration. In contrast, the PEG 
modification, being very hydrophilic and less positively 
charged, enables NPs to more easily navigate the extra-
cellular space and penetrate deeper into the spheroid tis-
sue at the expense of internalization.
In living subjects, circulating NPs can preferentially 
lodge in tumor tissue by extravasating from fenestrated 
capillaries [59] as a result of the enhanced permeabil-
ity and retention effect (EPR). Nevertheless, it has been 
shown that NP diffusive transport only extends about 
30–50 μm away from the vessels [60, 61]. Consequently, 
therapeutics released from these NPs may not attain 
cytotoxic concentrations and also fail to affect quiescent 
(non-cycling) cells in regions distal to the vasculature 
[62]. Previously, we evaluated drug and NP transport in 
2D and 3D cell culture, showing that nanoparticles lay-
ered with combinations of hexadecanethiol, phosphati-
dylcholine and high-density lipoprotein diffused deeper 
than PEGylated NPs into 3D cell culture representing 
hypo-vascularized tissue [63]. The NPs were uptaken 
in solid tumor tissue in  vivo [64], and elicited distinc-
tive drug release kinetics when loaded with paclitaxel or 
cisplatin [65]. Cytotoxicity experiments with free drug 
showed a substantial differential between 2D and 3D cell 
cultures, highlighting the increased resistance due to dif-
fusive transport [34], although the drug-loaded layered 
NPs were substantially more efficacious in 3D cell culture 
than free-drug. While these findings are consistent with 
previous work showing decreased efficacy in 3D cell cul-
ture compared to monolayer [32, 60], they offer hope that 
modification of NPs to enhance their uptake and trans-
port in cancerous tissue can help overcome the limita-
tions of diffusive transport.
Conclusions
The results of this study suggest the potential usefulness 
of combination treatment employing a blend of different 
NP formulations to achieve internalization of therapeu-
tics in cancerous tissue, e.g., in which PEG NPs are used 
for deep penetration into tissue distal from vasculature 
while MPG particles target proliferative regions close to 
blood vessels. Pathological examination of biopsy tissue 
could help to inform this approach. Interestingly, while 
the hybrid MPG/PEG NPs had similarly high uptake as 
MPG after 24  h in 3D cell culture, this group did not 
benefit from the combination of the cell penetrating and 
stealth attributes, and actually had a lower uptake and 
penetration depth than either MPG or PEG alone. In this 
case, internalization and diffusion may be competitive 
and thus inhibit overall NP uptake and transport. These 
results highlight the well-known need for a proper bal-
ance of NP properties to achieve both adequate inter-
nalization and diffusion, and emphasize that NP delivery 
assessment would benefit not only from consideration of 
different time points but also from evaluation of diffusive 
transport.
Future studies could potentially assess in further detail 
the time-dependent uptake of each NP group in mon-
olayer as well as in 3D cell culture. The delivery of thera-
peutic agents (drug, siRNA, proteins) could be studied 
to assess efficacy. Evaluation in  vivo would help estab-
lish NP distribution and clearance, as well as systemic 
toxicity. Additionally these studies would benefit from 
experimental as well as computational analysis [34, 42, 
44, 66–69] to elucidate the complex interactions between 
NP parameters (surface modifications and transport), cell 
types (tumorigenic vs. normal), and the tumor micro-
environment (cellular proliferation and death as a func-




Avidin-palmitate was conjugated to NP surfaces as previ-
ously described [31, 70, 71] for subsequent reaction with 
biotinylated ligands: MPG, PEG, VIM, and an equimolar 
combination of MPG/PEG. Briefly, 40  mg of avidin was 
dissolved in 4.8 mL of 2 % sodium deoxycholate (NaDC) 
in phosphate buffered saline (PBS) warmed to 37  °C. 
Palmitic acid-N- hydroxysuccinimide ester (PA-NHS, 
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Sigma) was dissolved in 2 % NaDC at 1 mg/mL and soni-
cated until well-mixed. 3.2 mL of the 1 mg/mL PA-NHS 
solution was added dropwise to the reaction vial, and 
reacted overnight at 37  °C. The following day, the reac-
tion was dialyzed overnight in 1200 mL of 0.15 % NaDC 
in PBS heated to 37 °C. Free PA-NHS was removed using 
3500 molecular weight cut off (MWCO) dialysis tub-
ing, and the dialysis cassette contents were subsequently 
transferred to a vial and stored at 4 °C.
Nanoparticle synthesis
We synthesized and characterized PLGA NPs encap-
sulating a fluorescent dye, Coumarin 6 (C6), to evalu-
ate tumor penetration and distribution via fluorescence 
microscopy. From earlier studies [72–75] as well as our 
previous experiments, we have observed that negligible 
quantities (~1  %) of C6 are released from NPs. This is 
attributed to the hydrophobic nature of C6 encapsulated 
within hydrophobic NPs. Therefore, C6 detected in cells 
reflects NP distribution in or on the cells, not C6 release 
and distribution. C6 NPs were synthesized as previously 
described using an oil-in-water (o/w) single emulsion 
technique [31, 71]. Briefly, C6 was encapsulated into 
100-200  mg PLGA carboxyl-terminated polymer (0.55–
0.75  dL/g, LACTEL®). C6 was dissolved in methylene 
chloride (DCM) overnight at a concentration of 15  μg 
C6 per mg of PLGA. The following day, the solution was 
added dropwise to a 5 % polyvinyl alcohol (PVA) solution 
of equal volume, vortexed and sonicated. The resulting 
NPs were hardened during solvent evaporation for 3  h. 
For unmodified NPs, the NPs were washed after harden-
ing, and centrifuged 3 times at 4  °C in deionized water 
(diH2O) to remove residual solvent. For avidin-palmitate 
surface-modified NPs, a similar protocol was followed 
[31, 71, 73]. NP formulations were synthesized by add-
ing (1 mg/mL) avidin-palmitate to the 5 % PVA solution. 
NPs were collected after the first wash and incubated for 
30  min with biotinylated ligands at a molar ratio of 3:1 
ligand:avidin in PBS. After conjugation, the NPs were 
washed two more times with diH2O by centrifugation 
and subsequent washing. All NPs were frozen, lyophi-
lized, and stored at −20 °C until use.
Cell culture
VK2/E6E7 vaginal epithelial (VK2) and human cervical 
carcinoma (HeLa) immortalized cell lines were kindly 
provided by Dr. Kenneth Palmer’s lab (University of Lou-
isville). These cell lines were obtained and authenticated 
through ATCC. We selected the VK2/E6E7 cell line, since 
for intravaginal delivery these would be the first “normal” 
cells to encounter NP treatment. HeLa cells provide the 
ability to assess NP behavior against a cervical cancer 
cell line in vitro. VK2/E6E7 vaginal epithelial cells (VK2) 
were maintained in Defined Kerotinocyte-Serum Free 
medium (SFM) supplemented with Defined Keratino-
cyte-SFM Growth Supplement. HeLa cells were main-
tained in minimal essential media (MEM) supplemented 
with 10  % fetal bovine serum and 1  % penicillin–strep-
tomycin in standard culture conditions. Cell media was 
checked and changed daily.
Tumor spheroid formation
HeLa cells were used for tumor spheroid formation. 
Cells were grown to 80 % confluence before harvesting. 
Twenty-four well tissue culture plates (Corning) were 
coated with a 1  % (w/v) agarose gel 24  h before sphe-
roid formation to prevent cell adherence. For formation, 
100,000 cells were placed in each well and lightly shaken 
(100  rpm) for 15  min on a reciprocating shaker. After 
7–14 days of incubation, spheroid formation occurred by 
self-aggregation to sizes ranging from 500 to 1000 μm.
Monolayer (2D) cellular uptake and microscopy
2D cellular imaging of 1.5 and 24 h NP uptake and pene-
tration in HeLa and VK2 cells was performed via inverted 
epifluorescence microscopy [31]. VK2 and HeLa cells 
were seeded 24 h prior to NP administration in LabTek 
8-well chamber slides at a density of 50,000 and 40,000 
cells per well for 1.5 and 24 h uptake, respectively. For NP 
administration, NPs were massed out and dissolved to 
reach a final stock concentration of 0.6 mg/mL in PBS++ 
(containing CaCl2 and MgCl2) to aid cell adherence. One 
hundred microliters of fresh media were added to the 
cells, and NPs were then added to obtain a final NP con-
centration of 200 μg/mL.
After either 1.5 or 24 h incubation, cells were washed 
five times in 0.5 mL of 1X PBS to remove any unbound or 
non-internalized NPs. Cells were then fixed with 0.3 mL 
of 4  % paraformaldehyde and incubated for 10  min at 
room temperature (RT). Cells were subsequently washed 
twice with 0.5 mL of PBS and permeabilized with 0.3 mL 
of 0.1 % Triton X-100 in 1 % bovine serum albumin (BSA) 
PBS++ for 10  min at RT. After permeabilization, cells 
were incubated with 0.3  mL of 1:40 Texas Red Phalloi-
din in 1  % BSA PBS++ for 20  min at RT for cytoskel-
eton staining and were subsequently washed twice with 
0.5  mL PBS. Cells were then incubated with 0.3  mL of 
4 μg/mL Hoechst in 1 % BSA PBS++ for 10 min at 37 °C 
for nuclear staining. Finally, cells were washed twice in 
PBS and once in diH2O, then mounted in Vectashield 
non-hardening mounting medium (Vector Laboratories, 
VWR) and kept at 4 °C until imaged [31].
Inverted epifluorescence microscopy was utilized to 
assess cellular uptake of NPs in 2D monolayers. Briefly, 
cells were prepared as described above and imaged in 
8-well LabTek chamber slides using the following filter 
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settings: 4′,6-diamidino-2-phenylindole (DAPI) to visu-
alize Hoechst, green fluorescent protein (GFP) for C6, 
and the Texas Red channel to evaluate NP uptake in 
2D. Exposure times for DAPI, GFP, and Texas Red were 
kept consistent throughout experiments and were as fol-
lows: DAPI at 45 ms (excitation/emissions: 358/461 nm); 
GFP at 60  ms (593/615  nm); and Texas Red at 180  ms 
(488/515 nm).
Spheroid (3D) cellular uptake and microscopy
To assess the differences in NP uptake and distribution 
through hypo-vascularized tumor tissue, HeLa spheroids 
were incubated with 0.01  mg/mL of NPs and visualized 
using confocal microscopy. Diffusion profiles through 
the spheroids for each NP formulation were evaluated by 
quantifying the fluorescence intensity in z-stack images 
as a function of distance from the spheroid periphery. 
After NP administration, tumor spheroids were trans-
ferred to LabTek 8-well chamber slides for fluorescent 
staining and were washed five times with 0.2  mL 1X 
PBS. Tumor spheroids were subsequently incubated for 
10 min at RT with 0.2 mL 4 % paraformaldehyde for sphe-
roid fixation. Following fixation, spheroids were washed 
twice with 0.2  mL of PBS, followed by incubation with 
0.2 mL of 1:40 Texas Red Phalloidin in 1 % BSA PBS++ 
for 20  min at RT for cytoskeleton staining. Spheroids 
were then washed twice with 0.2 mL PBS and incubated 
with 0.2 mL of 4 μg/mL Hoechst in 1 % BSA PBS++ for 
10  min at 37  °C for nuclear staining. Finally, spheroids 
were washed twice in 0.2  mL PBS and once in 0.2  mL 
diH2O. Spheroids were then mounted with Vectashield 
non-hardening mounting medium. 3D uptake and dis-
tribution of NPs through tumor spheroids was assessed 
using confocal microscopy. Images were processed using 
ImageJ by taking representative samples from tumor 
cross-sections (≥90 averaged profiles for each sample).
Flow cytometry analysis
Cells were plated in 6-well plates (Corning) at a density 
of 200,000 cells per well. Both VK2 and HeLa cell lines 
were incubated with NP suspensions at 0.05 mg/mL for 
either 1.5 or 24 h in a 37 °C humidified chamber in the 
appropriate medium [31]. An unmodified NP control 
group was used to compare uptake relative to surface-
modified NPs, as our previous work demonstrated mini-
mal difference between unmodified and avidin-modified 
NP association and uptake [31]. After incubation, the 
cells were washed five times with PBS++. Next, the 
cells were dissociated with enzyme-free cell dissociation 
buffer (ThermoFisher). The dissociated cells were moved 
to FACS tubes, centrifuged, and resuspended in a FACS 
buffer solution containing 1  % BSA and 0.1  % sodium 
azide. From each sample, half the cells were moved to 
separate FACS tubes and kept on ice until analyzed (total 
associated samples). The remaining cells were exposed 
to 0.4  % trypan blue for 5  min to quench extracellular 
fluorescence, washed twice in FACS buffer, and kept on 
ice until analyzed (internalized samples) [31]. All FACS 
tubes from both groups were analyzed using a BD LSR-
Fortessa Flow Cytometer (BD Biosciences). Data were 
analyzed using FlowJo software (FlowJo Enterprise), and 
a minimum of 10,000 cells were analyzed per sample. 
For flow cytometry analysis of tumor spheroids, a simi-
lar protocol was followed using spheroids after 7 days of 
growth. Instead of enzyme-free cell dissociation buffer, 
0.25  % Trypsin–EDTA was used to fully disaggregate 
the spheroids before centrifugation and resuspension in 
FACS buffer solution.
Statistical analysis
Experiments were conducted each with a minimum sam-
ple size of n = 3. Data were analyzed by applying Tukey’s 
test with significance p < 0.05. Unless otherwise noted, all 
figure error bars represent the standard deviation of the 
measurements. To enable clear interpretation, statisti-
cally similar results are shown linked with an overbar in 
the figures of the “Results” section.
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